Key facts
- This page summarizes Craig A. Tooman's Form 3 filing for Silence Therapeutics plc (SLN).
- 0 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 02 Jan 2025, 16:39.
Craig A. Tooman - 02 Jan 2025 Form 3 Insider Report for Silence Therapeutics plc (SLN)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- SLN
- Reported as of
- 02 Jan 2025
- Net transaction value
- $0
- Reporting owner signature
- /s/ Rhonda Hellums, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Craig A. Tooman filed Form 3 for Silence Therapeutics plc (SLN) on 02 Jan 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SLN
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,486
- Date
- 02 Jan 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLN
holding
Derivative
Employee Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Jan 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 580,000
- Exercise price
- $7.02
- Footnotes
- F1
SLN
holding
Derivative
Employee Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Jan 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 264,999
- Exercise price
- $7.87
- Footnotes
- F2
SLN
holding
Derivative
Employee Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Jan 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 375,000
- Exercise price
- $6.33
- Footnotes
- F3
SLN
holding
Derivative
Employee Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Jan 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 900,000
- Exercise price
- $3.86
- Footnotes
- F4
SLN
holding
Derivative
Employee Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Jan 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 2,100,000
- Exercise price
- $5.13
- Footnotes
- F5
SLN
holding
Derivative
Employee Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Jan 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 216,960
- Exercise price
- $3.33
- Footnotes
- F6
SLN
holding
Derivative
Employee Share Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Jan 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 650,880
- Exercise price
- $5.90
- Footnotes
- F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
One fourth (1/4th) of the shares subject to the option award vested on January 6, 2022, and one twelfth (1/12th) of the remaining shares subject to the option award vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Footnote F2
This option vested or shall vest in equal monthly installments over a four-year period measured from one month following January 6, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
Footnote F3
This option vested or shall vest in equal monthly installments over a four-year period measured from one month following February 21, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
Footnote F4
This option vested or shall vest in equal monthly installments over a five-year period measured from one month following September 16, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date.
Footnote F5
This option vested or shall vest in equal monthly installments over a four-year period measured from one month following January 5, 2023, subject to the Reporting Person's continuous service as of the applicable vesting date.
Footnote F6
One fourth (1/4th) of the shares subject to the option vested on September 14, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.
Footnote F7
One fourth (1/4th) of the shares subject to the option shall vest on January 4, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.